NCT05926336Source recordAI-normalized
To Compare the Effects of Intraoperative Use of Intravenous Anesthetics Propofol and Inhaled Anesthetics Sevoflurane on the Prognosis of Patients Undergoing Surgery for Primary Brain, Liver, Lung, and Ovarian Cancer Tumors and the Investigation of Its Mechanism of Action
This clinical trial, sponsored by Kaohsiung Medical University Chung-Ho Memorial Hospital, is currently recruiting participants and aims to elucidate the impact of different anesthetic techniques on cancer surgery outcomes. The findings could have significant implications for clinical practice in anesthesiology and oncology, potentially influencing anesthetic protocols in surgical oncology. Given the high incidence of these cancers, successful outcomes may enhance the market positioning of the involved anesthetics and lead to increased adoption in surgical settings. The trial's results could also inform future product development and marketing strategies for anesthetic agents, particularly in the context of cancer care.
AI analysis
Indication: Lung Cancer
Modality: small molecule
Target: The study investigates the comparative effects of intravenous anesthetic Propofol and inhaled anesthetic Sevoflurane on the prognosis of patients undergoing surgery for primary brain, liver, lung, and ovarian cancer tumors, focusing on overall survival and postoperative complications.
Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
Source URL: ClinicalTrials.gov
Source updated: Sep 28, 2023
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Lung Cancer
View original source fields
Condition raw: Lung Cancer, Brain Tumor, Liver Cancer, Ovarian Cancer
Condition normalized: Lung Cancer, Brain Tumor, Liver Cancer, Ovarian Cancer
Modality raw: small molecule
Modality normalized: small molecule
Target raw: The study investigates the comparative effects of intravenous anesthetic Propofol and inhaled anesthetic Sevoflurane on the prognosis of patients undergoing surgery for primary brain, liver, lung, and ovarian cancer tumors, focusing on overall survival and postoperative complications.
Target normalized: The study investigates the comparative effects of intravenous anesthetic Propofol and inhaled anesthetic Sevoflurane on the prognosis of patients undergoing surgery for primary brain, liver, lung, and ovarian cancer tumors, focusing on overall survival and postoperative complications.
NCT04606446Source recordAI-normalized
A PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS
PF-07248144, developed by Pfizer, is currently undergoing a Phase 1/2A clinical trial targeting advanced or metastatic solid tumors, specifically focusing on ER+HER2- breast cancer, castration-resistant prostate cancer (CRPC), and non-small cell lung cancer (NSCLC). The trial's design includes both monotherapy and combination therapy approaches, which may enhance its market potential by addressing treatment-resistant cancers. The competitive landscape includes established therapies such as CDK4/6 inhibitors and endocrine therapies, necessitating a strong efficacy and safety profile to differentiate PF-07248144. Given the increasing prevalence of these cancers and the demand for novel treatment options, successful outcomes could position PF-07248144 favorably within a lucrative oncology market. The estimated enrollment of 320 participants indicates a robust commitment to generating significant clinical data, which could attract interest from investors and stakeholders in the oncology space.
AI analysis
Indication: Locally Advanced or Metastatic ER+ HER2- Breast Cancer
Modality: small molecule
Target: KAT6 Inhibitor
Sponsor: Pfizer
Source URL: ClinicalTrials.gov
Source updated: Apr 16, 2026
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Locally Advanced or Metastatic Non-small Cell Lung Cancer
View original source fields
Condition raw: Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
Condition normalized: Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
Modality raw: small molecule
Modality normalized: small molecule
Target raw: KAT6 Inhibitor
Target normalized: KAT6 Inhibitor
NCT02357836Source recordAI-normalized
Phase 0 Pharmacodynamic Study of the Effects of Itraconazole on Tumor Angiogenesis and the Hedgehog Pathway in Early-stage Non-small Cell Lung Cancer
The Phase 0 study of itraconazole in early-stage non-small cell lung cancer (NSCLC) aims to explore its pharmacodynamic effects on tumor angiogenesis and the Hedgehog pathway. Given the high prevalence of NSCLC and the limited treatment options available for early-stage patients, this study could position itraconazole as a novel therapeutic option, particularly in combination with surgical resection. The findings may enhance the competitive landscape for NSCLC treatments, especially against existing anti-angiogenic therapies. Investors and stakeholders should consider the implications of these results on market positioning and potential partnerships for further development.
AI analysis
Indication: Non-small Cell Lung Cancer
Modality: small molecule
Target: Tumor angiogenesis and Hedgehog (Hh) pathway modulation
Sponsor: University of Texas Southwestern Medical Center
Source URL: ClinicalTrials.gov
Source updated: May 03, 2021
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Non-small Cell Lung Cancer
View original source fields
Condition raw: Non-small Cell Lung Cancer
Condition normalized: Non-small Cell Lung Cancer
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Tumor angiogenesis and Hedgehog (Hh) pathway modulation
Target normalized: Tumor angiogenesis and Hedgehog (Hh) pathway modulation
NCT07020117Source recordAI-normalized
NECTINIUM-2: A Phase 1b, 2 Part, Multicenter, Single Arm, Open Label Study to Evaluate the Safety and Efficacy of a Nectin-4 Radiopharmaceutical ([225Ac]Ac-AKY-1189) in Patients With Previously Treated Locally Advanced or Metastatic Solid Tumors
This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical (\[225Ac\]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to establish the maximum tolerated dose (MTD) or maximum administered dose (MAD) and the recommended Phase 2 dose.
AI analysis
Indication: Urothelial Carcinoma Bladder
Modality: small molecule
Target: [225Ac]Ac-AKY-1189 (therapeutic), [64Cu]Cu-AKY-1189 (imaging)
Sponsor: Aktis Oncology, Inc.
Source URL: ClinicalTrials.gov
Source updated: Apr 21, 2026
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Non Small Cell Lung Cancer
View original source fields
Condition raw: Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC), Hormone Receptor Positive Breast Adenocarcinoma, Non Small Cell Lung Cancer, Cervical Adenocarcinoma, Colorectal Adenocarcinoma, Head and Neck Cancer
Condition normalized: Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC), Hormone Receptor Positive Breast Adenocarcinoma, Non Small Cell Lung Cancer, Cervical Adenocarcinoma, Colorectal Adenocarcinoma, Head and Neck Cancer
Modality raw: small molecule
Modality normalized: small molecule
Target raw: [225Ac]Ac-AKY-1189 (therapeutic), [64Cu]Cu-AKY-1189 (imaging)
Target normalized: [225Ac]Ac-AKY-1189 (therapeutic), [64Cu]Cu-AKY-1189 (imaging)
NCT07246863Source recordAI-normalized
Ph 2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab and Nivolumab With or Without Docetaxel Versus Docetaxel in 2L Treatment of Participants With Metastatic NSCLC (GDFATHER-NSCLC-02)
This is an exploratory, signal-finding, randomized, placebo-controlled, blinded, multi-center phase 2b trial of the anti-GDF-15 antibody Visugromab (CTL-002) at two different dose levels plus Nivolumab with Docetaxel versus Visugromab at the higher dose plus Nivolumab with placebo versus double-placebo with Docetaxel, in participants that receive second-line treatment for non-squamous NSCLC after failure of prior first-line treatment including a CPI (checkpoint inhibitor). The trial consists of 3 Parts: an open-label Safety Run-in part (Part A) followed by a subsequent randomized phase 2b part with 4 treatment arms. After the treatment of 15 participants with visugromab at the expansion dose, an interim safety and preliminary efficacy analysis will be conducted (Part B), followed by the treatment of the remaining participants (Part C).
AI analysis
Indication: Metastatic Non-Squamous Non-Small Cell Lung Cancer
Modality: monoclonal antibody
Target: Visugromab RDE (recommended dose for expansion), Visugromab 6mg/kg, Nivolumab, Placebo Saline Infusion, Docetaxel
Sponsor: CatalYm GmbH
Source URL: ClinicalTrials.gov
Source updated: Jun 09, 2026
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Metastatic Non-Squamous Non-Small Cell Lung Cancer
View original source fields
Condition raw: Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
Condition normalized: Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Visugromab RDE (recommended dose for expansion), Visugromab 6mg/kg, Nivolumab, Placebo Saline Infusion, Docetaxel
Target normalized: Visugromab RDE (recommended dose for expansion), Visugromab 6mg/kg, Nivolumab, Placebo Saline Infusion, Docetaxel
NCT07155200Source recordAI-normalized
Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
Although small cell lung cancer (SCLC) responds dramatically to initial platinum-based chemotherapy, recurrences are nearly universal. The addition of atezolizumab, an immune checkpoint inhibitor, to front-line chemotherapy has recently demonstrated an improvement in overall survival (OS) in extensive stage SCLC (ES-SCLC). Subsequent lines of therapies are associated with modest efficacy in patients with relapsed disease, and the median overall survival is still 12 to 13 months at best. Cirtuvivint is a small molecule inhibitor of the CDC2-like kinases (CLKs) and dual-specificity tyrosine-regulated kinases (DYRKs); inhibiting CLKs and DYRKs has been shown in preclinical models to cause tumor growth inhibition and sensitize cancer cells to cytotoxic chemotherapy. This study is testing the hypothesis that adding cirtuvivint to chemotherapy in patients with relapsed SCLC will be well tolerated and improve the response rate and progression-free survival (PFS).
AI analysis
Indication: Small-cell Lung Cancer
Modality: small molecule
Target: Cirtuvivint, Irinotecan
Sponsor: Washington University School of Medicine
Source URL: ClinicalTrials.gov
Source updated: Dec 22, 2025
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Small-cell Lung Cancer
View original source fields
Condition raw: Small-cell Lung Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer
Condition normalized: Small-cell Lung Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Cirtuvivint, Irinotecan
Target normalized: Cirtuvivint, Irinotecan
NCT04951648Source recordAI-normalized
A Randomized Controlled, Open-lable, Phase III, Multicenter Clinical Study of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation
To assess the efficacy and safety of Almonertinib versus platinum-based chemotherapy as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutation.
AI analysis
Indication: Non-small Cell Lung Cancer
Modality: small molecule
Target: Almonertinib, chemotherapy
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Source URL: ClinicalTrials.gov
Source updated: Jul 07, 2021
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Non-small Cell Lung Cancer
View original source fields
Condition raw: Non-small Cell Lung Cancer
Condition normalized: Non-small Cell Lung Cancer
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Almonertinib, chemotherapy
Target normalized: Almonertinib, chemotherapy
NCT04840758Source recordAI-normalized
A Prospective Single-arm Single-center Clinical Study：Assessment of the Safety and Effects of Stereotactic Ablation Radiotherapy (SABR) Combined With Sintilimab in Early Inoperable Synchronous Multiple Primary Lung Cancer (sMPLC)
The purpose of this study is to assess of the Safety and Effects of Stereotactic Ablation Radiotherapy (SABR) combined with Sintilimab in early inoperable synchronous Multiple Primary Lung Cancer (sMPLC)
AI analysis
Indication: Multiple Primary Lung Cancer
Modality: monoclonal antibody
Target: Stereotactic Ablation Radiotherapy, Sintilimab
Sponsor: The First Affiliated Hospital of Xiamen University
Source URL: ClinicalTrials.gov
Source updated: Apr 12, 2021
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Multiple Primary Lung Cancer
View original source fields
Condition raw: Multiple Primary Lung Cancer
Condition normalized: Multiple Primary Lung Cancer
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Stereotactic Ablation Radiotherapy, Sintilimab
Target normalized: Stereotactic Ablation Radiotherapy, Sintilimab
NCT06208033Source recordAI-normalized
A Single-arm, Sequential Study Assessing the Efficacy and Safety of SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC) : First-line Treatment or Failed From First-line Immune Checkpoint Inhibitor Treatment.
This is a single-arm, sequential study assessing the efficacy and safety of SMET12 and Toripalimab combined chemotherapy in patients with EGFR positive advanced non-small cell lung cancer (NSCLC) : first-line treatment or failed from first-line immune checkpoint inhibitor treatment.The primary objective is to evaluate the anti-tumor activity and safety of SMET12 and Toripalimab combined chemotherapy in patients with EGFR positive advanced NSCLC.
AI analysis
Indication: EGFR Positive Non-small Cell Lung Cancer
Modality: small molecule
Target: SMET12, SMET12, SMET12
Sponsor: Fujian Cancer Hospital
Source URL: ClinicalTrials.gov
Source updated: Jan 17, 2024
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: EGFR Positive Non-small Cell Lung Cancer
View original source fields
Condition raw: EGFR Positive Non-small Cell Lung Cancer
Condition normalized: EGFR Positive Non-small Cell Lung Cancer
Modality raw: small molecule
Modality normalized: small molecule
Target raw: SMET12, SMET12, SMET12
Target normalized: SMET12, SMET12, SMET12
NCT03761914Source recordAI-normalized
A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers
To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
AI analysis
Indication: Acute Myelogenous Leukemia
Modality: monoclonal antibody
Target: galinpepimut-S, pembrolizumab, Montanide, GM-CSF
Sponsor: Sellas Life Sciences Group
Source URL: ClinicalTrials.gov
Source updated: Nov 19, 2024
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Small-cell Lung Cancer
View original source fields
Condition raw: Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer
Condition normalized: Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: galinpepimut-S, pembrolizumab, Montanide, GM-CSF
Target normalized: galinpepimut-S, pembrolizumab, Montanide, GM-CSF
NCT00864721Source recordAI-normalized
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
The purpose of this research study is to find out what effects (good and bad) sunitinib has on patients and their NSCLC.
AI analysis
Indication: Non Small Cell Lung Cancer
Modality: small molecule
Target: Sutent
Sponsor: US Oncology Research
Source URL: ClinicalTrials.gov
Source updated: Oct 16, 2018
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Non Small Cell Lung Cancer
View original source fields
Condition raw: Non Small Cell Lung Cancer
Condition normalized: Non Small Cell Lung Cancer
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Sutent
Target normalized: Sutent
NCT04194944Source recordAI-normalized
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
The reason for this study is to see if the study drug selpercatinib compared to a standard treatment is effective and safe in participants with rearranged during transfection (RET) fusion-positive non-squamous non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.
AI analysis
Indication: Non-Small Cell Lung Cancer
Modality: small molecule
Target: Selpercatinib, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Sponsor: Eli Lilly and Company
Source URL: ClinicalTrials.gov
Source updated: Oct 21, 2025
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Non-Small Cell Lung Cancer
View original source fields
Condition raw: Non-Small Cell Lung Cancer
Condition normalized: Non-Small Cell Lung Cancer
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Selpercatinib, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Target normalized: Selpercatinib, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
NCT02481830Source recordAI-normalized
An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First Line Chemotherapy (CheckMate 331: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 331)
The purpose of this study is to compare the overall survival of nivolumab versus chemotherapy in subjects with relapsed SCLC.
AI analysis
Indication: Lung Cancer
Modality: monoclonal antibody
Target: Nivolumab, Topotecan, Amrubicin
Sponsor: Bristol-Myers Squibb
Source URL: ClinicalTrials.gov
Source updated: Jul 27, 2023
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Lung Cancer
View original source fields
Condition raw: Lung Cancer
Condition normalized: Lung Cancer
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Nivolumab, Topotecan, Amrubicin
Target normalized: Nivolumab, Topotecan, Amrubicin
NCT00707304Source recordAI-normalized
FORTIS-M: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Oral Talactoferrin in Addition to Best Supportive Care in Patients With Non-small Cell Lung Cancer Who Have Failed Two or More Prior Treatment Regimens
The FORTIS-M trial evaluated the safety and efficacy of talactoferrin in patients with non-small cell lung cancer (NSCLC) who had failed two or more prior treatment regimens. The study aimed to determine if talactoferrin could improve overall survival when combined with best supportive care.
AI analysis
Indication: Non Small Cell Lung Cancer
Modality: small molecule
Target: Non-small Cell Lung Cancer
Sponsor: Agennix
Source URL: ClinicalTrials.gov
Source updated: Aug 21, 2012
Ingested: May 30, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Non Small Cell Lung Cancer
View original source fields
Condition raw: Non Small Cell Lung Cancer
Condition normalized: Non Small Cell Lung Cancer
Modality raw: Non Small Cell Lung Cancer
Modality normalized: small molecule
Target raw: Non-small Cell Lung Cancer
Target normalized: Non-small Cell Lung Cancer
NCT00193245Source recordAI-normalized
A Randomized Trial of Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer
This clinical trial evaluated the efficacy and toxicity of oral topotecan compared to intravenous docetaxel in patients with relapsed or progressive non-small cell lung cancer. Conducted by SCRI Development Innovations, LLC, the study involved 80 participants and aimed to determine overall response rates and secondary outcomes such as time to progression and overall survival.
AI analysis
Indication: Lung Cancer
Modality: small molecule
Target: Non-Small Cell Lung Cancer
Sponsor: SCRI Development Innovations, LLC
Source URL: ClinicalTrials.gov
Source updated: Jun 28, 2010
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Lung Cancer
View original source fields
Condition raw: Lung Cancer
Condition normalized: Lung Cancer
Modality raw: Lung Cancer
Modality normalized: small molecule
Target raw: Non-Small Cell Lung Cancer
Target normalized: Non-Small Cell Lung Cancer
NCT01027598Source recordAI-normalized
A Randomized Phase II Double-Blind Trial of Erlotinib and Pazopanib, or Erlotinib and Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
This trial evaluated the efficacy of combining erlotinib with pazopanib versus erlotinib alone in patients with previously treated advanced NSCLC. The study aimed to improve progression-free survival (PFS) by targeting both EGFR and VEGFR pathways.
AI analysis
Indication: Non Small Cell Lung Cancer
Modality: small molecule
Target: Non-Small Cell Lung Cancer (NSCLC)
Sponsor: SCRI Development Innovations, LLC
Source URL: ClinicalTrials.gov
Source updated: Jan 29, 2016
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Non Small Cell Lung Cancer
View original source fields
Condition raw: Non Small Cell Lung Cancer
Condition normalized: Non Small Cell Lung Cancer
Modality raw: Non Small Cell Lung Cancer
Modality normalized: small molecule
Target raw: Non-Small Cell Lung Cancer (NSCLC)
Target normalized: Non-Small Cell Lung Cancer (NSCLC)
NCT01963923Source recordAI-normalized
Effectiveness of a Preoperative Pulmonary Rehabilitation Program in Exercise Tolerance and Quality of Life in Patients Awaiting Lung Resection by Video-assisted Thoracic Surgery
This clinical trial evaluated the effectiveness of a preoperative pulmonary rehabilitation program on exercise tolerance and quality of life in patients awaiting lung resection via video-assisted thoracic surgery. The study involved 40 patients, with a focus on improving outcomes through a structured rehabilitation program.
AI analysis
Indication: Lung Cancer
Modality: medical device
Target: Lung Cancer
Sponsor: Universidade da Coruña
Source URL: ClinicalTrials.gov
Source updated: May 01, 2020
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Lung Cancer
View original source fields
Condition raw: Lung Cancer
Condition normalized: Lung Cancer
Modality raw: Lung Cancer
Modality normalized: medical device
Target raw: Lung Cancer
Target normalized: Lung Cancer
NCT07398027Source recordAI-normalized
Post-Market Study of Transbronchial Cryo-assisted RFA During Robotic Assisted Bronchoscopy With Subsequent Surgical Resection (CRONOS-CH)
Post-Market Study of Transbronchial Cryo-assisted RFA During Robotic Assisted Bronchoscopy With Subsequent Surgical Resection (CRONOS-CH) is a NA clinical asset sponsored by Carolin Steinack in Lung Cancer. SEO and diligence focus: HybridTherm® System, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
AI analysis
Indication: Lung Cancer
Modality: medical device
Target: HybridTherm® System
Sponsor: Carolin Steinack
Source URL: ClinicalTrials.gov
Source updated: Feb 09, 2026
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Lung Cancer
View original source fields
Condition raw: Lung Cancer
Condition normalized: Lung Cancer
Modality raw: non-small cell lung cancer
Modality normalized: medical device
Target raw: HybridTherm® System
Target normalized: HybridTherm® System
NCT03521154Source recordAI-normalized
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, International Study of Osimertinib as Maintenance Therapy in Patients With Locally Advanced, Unresectable EGFR Mutation-positive Non-Small Cell Lung Cancer (Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy (LAURA).
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, International Study of Osimertinib as Maintenance Therapy in Patients With Locally Advanced, Unresectable EGFR Mutation-positive Non-Small Cell Lung Cancer (Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy (LAURA). is a PHASE3 clinical asset sponsored by AstraZeneca in Non Small Cell Lung Cancer (Stage III). SEO and diligence focus: Osimertinib 80mg/40mg, Placebo Osimertinib 80mg/40mg, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
AI analysis
Indication: Non Small Cell Lung Cancer (Stage III)
Modality: small molecule
Target: Osimertinib 80mg/40mg, Placebo Osimertinib 80mg/40mg
Sponsor: AstraZeneca
Source URL: ClinicalTrials.gov
Source updated: May 05, 2026
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Non Small Cell Lung Cancer (Stage III)
View original source fields
Condition raw: Non Small Cell Lung Cancer (Stage III)
Condition normalized: Non Small Cell Lung Cancer (Stage III)
Modality raw: non-small cell lung cancer
Modality normalized: small molecule
Target raw: Osimertinib 80mg/40mg, Placebo Osimertinib 80mg/40mg
Target normalized: Osimertinib 80mg/40mg, Placebo Osimertinib 80mg/40mg
NCT06123754Source recordAI-normalized
A Randomized, Controlled, Double-blind, Multicenter Phase III Clinical Study of Envafolimab Plus Platinum-based Doublet Chemotherapy Versus Placebo Plus Platinum-based Doublet Chemotherapy in Patients With Non-small Cell Lung Cancer
A Randomized, Controlled, Double-blind, Multicenter Phase III Clinical Study of Envafolimab Plus Platinum-based Doublet Chemotherapy Versus Placebo Plus Platinum-based Doublet Chemotherapy in Patients With Non-small Cell Lung Cancer is a PHASE3 clinical asset sponsored by 3D Medicines (Sichuan) Co., Ltd. in Non-small Cell Lung Cancer. SEO and diligence focus: Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection, placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
AI analysis
Indication: Non-small Cell Lung Cancer
Modality: monoclonal antibody
Target: Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection, placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection
Sponsor: 3D Medicines (Sichuan) Co., Ltd.
Source URL: ClinicalTrials.gov
Source updated: Mar 25, 2026
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Non-small Cell Lung Cancer
View original source fields
Condition raw: Non-small Cell Lung Cancer
Condition normalized: Non-small Cell Lung Cancer
Modality raw: non-small cell lung cancer
Modality normalized: monoclonal antibody
Target raw: Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection, placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection
Target normalized: Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection, placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection